News

Vivos Therapeutics to Report Financial Results and Call Details

Vivos Therapeutics to Report Financial Results and Call Details

Vivos Therapeutics to Announce Second Quarter Financials

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a trailblazer in medical device technology, is set to release its financial results for the second quarter of 2025. The announcement marks a significant point for the company, which specializes in developing effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe cases in children.

Details of the Financial Release

The much-anticipated financial results will be released after market closure, allowing stakeholders to digest the information thoroughly. Following the results announcement, Vivos Therapeutics will host a conference call at 5:00 PM Eastern Time. This call provides an invaluable opportunity for investors to gain insights into the company's recent achievements and strategic plans moving forward.

Participating in the Conference Call

Investors and interested parties can access the conference call by dialing (800) 717-1738, with international callers using (646) 307-1865. A replay of the call will be made available shortly after its conclusion, accessible at (844) 512-2921 for domestic callers and (412) 317-6671 for international participants. The replay will remain available until early September, providing ample time for review.

Accessing the Live Webcast

For those who prefer a digital format, Vivos Therapeutics encourages everyone to view the live webcast on their official website. The recording will also be archived for 30 days for those unable to attend the live session, ensuring accessibility for all interested stakeholders.

About Vivos Therapeutics

Vivos Therapeutics, Inc. is dedicated to improving the lives of individuals suffering from sleep disorders linked to dentofacial abnormalities. The company is committed to addressing the needs of OSA and snoring patients through innovative devices such as their Complete Airway Repositioning and Expansion (CARE) systems. These products have gained FDA clearance for treating OSA in patients aged 6 to 17, making Vivos the first provider to secure such approval for children.

The Impact of OSA Worldwide

With over 1 billion individuals affected by OSA globally, the condition remains alarmingly underdiagnosed, with approximately 90% of those affected unaware of their situation. This serious condition is intertwined with several health complications. Traditional treatments like CPAP often overlook the root causes, highlighting the importance of Vivos' approach.

Vivos' Unique Approach

Founded in 2016, Vivos Therapeutics is carving a niche in the medical field through education, technology, and strategic collaborations. Their methodology, known as The Vivos Method, emphasizes a nonsurgical, noninvasive, and nonpharmaceutical approach to treatment, providing hope to those who seek to breathe freely and lead healthier lives.

Continuing Innovations in Sleep Health

Vivos is continuously working to innovate within the realm of sleep health. By acquiring sleep healthcare practices and developing cutting-edge technology, the company is positioned to further revolutionize how sleep disorders, particularly OSA, are diagnosed and treated.

Frequently Asked Questions

What is Vivos Therapeutics focusing on in their upcoming release?

Vivos Therapeutics will announce its financial results and discuss recent milestones and future developments.

How can one participate in the conference call?

Interested parties can join the conference call by dialing the specified phone numbers shared by Vivos Therapeutics.

What products does Vivos specialize in?

Vivos focuses on proprietary treatments for sleep-related breathing disorders, particularly for individuals with obstructive sleep apnea.

Why is the upcoming financial report significant?

The financial report presents an opportunity to assess Vivos' performance and strategic developments in the last quarter.

How does Vivos support OSA patients?

Through innovative technologies and The Vivos Method, the company addresses the needs of OSA and snoring patients effectively and compassionately.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 0

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 78

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 25

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 85

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 59

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 102

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading